The DOI matches its Crossref record; 5 of the 6 references it cites were found in a registry or an index; none of the 2 sources its claims cite is checked for support yet.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Open accessAbstract
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months ...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 2 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 109 days (95% CI, 92 to 136) calculated with the use of a power-law model (at day 119)”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 66 days (95% CI, 59 to 72) and 182 days (95% CI, 153 to 254) for live-virus neutralization.”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated half-life of binding antibodies after day 43 for all the participants was 52 days (95% CI, 46 to 58) calculated with the use of an exponential decay model”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“49,373 (95% CI, 25,171 to 96,849) in those 71 years of age or older.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As measured by ΔAICc (change in Akaike information criterion, corrected for small sample size), the best fit for binding and neutralization were the power-law and exponential decay models, respectively”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“62,424 (95% CI, 36,765 to 105,990) in those 56 to 70 years of age”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these GMTs were lower in participants 56 to 70 years of age (P=0.03) and in those 71 years of age or older (P=0.005) than in those 18 to 55 years of age”
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 2
In the paper
“Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1”
What the sources say
- Not checked yetcites [1] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403- 416. 33378609 PMC7787219 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“These results are consistent with published observations of convalescent patients with Covid-19 through 8 months after symptom onset.5”
What the sources say
- Not checked yetcites [5] Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063- eabf4063. 33408181 PMC7919858 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The durability of protection from the mRNA-1273 vaccine is currently unknown.
“The durability of protection is currently unknown.”
The authors state this as an assumption.
The exponential decay model assumes a constant antibody decay rate over time.
“which assumes a steady decay rate over time”
The authors state this as an assumption.
The power-law model assumes that antibody decay rates decrease over time.
“which assumes that decay rates decrease over time”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current evidence suggests that circulating antibodies persist for at least 6 months postvaccination (7), although there is some decay from the peak levels achieved after the second dose.”
From mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern (2021) · cites this paper as [7]
In the citing paper
“We previously showed that vaccination with mRNA-1273 elicited antibodies to SARS-CoV-2 WA1 in subjects aged 56 to 70 and 71 and older that are as potent (15) and durable (13) as those elicited in adults aged 18 to 55, with a slight decrease in potency for the oldest subjects in live-virus neutralization (13).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In the pseudovirus neutralization assay, consistent with our previous study (13), 25% of sera neutralized WA1 after one dose (day 29).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In clinical trials, two doses of mRNA-1273 also elicited durable antibody responses over a period of 6 months. Although antibody titres declined slightly over the duration of the study, high neutralizing ability was retained across all age groups205.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [205]
In the citing paper
“Several reports have measured the decay of neutralizing antibody responses raised by mRNA COVID-19 vaccines with a half-life of 69-173 days (Doria-Rose et al., 2021; Levin et al., 2021).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Doria-Rose et al., 2021
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Self-citationImmunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citationDurability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722
Self-citation
Flagged first, then by citations
1 of the 6 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 646
Understanding Antibody Magnitude and Durability Following Vaccination Against Sars-Cov-2
Murphy, Q. M., Lewis, G. K., Sajadi, M. M., Forde, J. E., & Ciupe, S. M. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109274 · Cited by 2
Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?
Lippi, G., Henry, B. M., & Plebani, M. (2021) · Diagnostics · doi:10.3390/diagnostics11060941 · Cited by 2
Yelin, D., Rozen‐Zvi, B., Yahav, D., Ben-Dor, N., Steinmetz, T., Agur, T., Zingerman, B. V., Schneider, S., Lichtenberg, S., Ben‐Zvi, H., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac031 · Cited by 2
Immunological heterogeneity informs estimation of the durability of vaccine protection
de Cellès, M. D., Wong, A., Guevara, L. A. B., & Rohani, P. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0070 · Cited by 2
Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
Spitaleri, G., Aliaga, P. T., Catania, C., Signore, E. D., Attili, I., Santoro, C., Giugliano, F., Giachetti, P. P. M. B., Curigliano, G., Passaro, A., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.10.004 · Cited by 2
Kang, E. S., Oh, J. S., Lee, E., Hong, S., Ahn, S. M., Lee, C., Yoo, B., & Kim, Y. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e109 · Cited by 2
An, Z., Zhang, Y., Yu, X., Jia Hui, X. I. A., Yin, Y., Li, G., Lu, J., Fan, X., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051412 · Cited by 3
Feng, J., Wang, W.-J., Jin, P., Zheng, H., Jin, L., Xia, X., Zhang, X., Li, Z.-P., Li, J., & Zhu, F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2230760 · Cited by 2
Alzate-Ángel, J. C., Avilés-Vergara, P. A., Arango-Londoño, D., Concha-Eastman, A., Garcés-Hurtado, A., López‐Carvajal, L., Minotta-Díaz, I. L., Ortega-Lenis, D., Quintero, G., Reina-Bolaños, S., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1321327 · Cited by 2
Deisolation in the Healthcare Setting Following Recent COVID-19 Infection
Baumgart, S., McLachlan, A. R., Kenny, H., McKew, G. L., Maddocks, S., Chen, W., & Kok, J. (2024) · Viruses · doi:10.3390/v16071131 · Cited by 2
Unagami, K., Yoshikawa, M., Egawa, H., Ohfuji, S., Natori, Y., Oki, R., Mori, T., Hattori, H., Ishiwatari, A., Kanzawa, T., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126221 · Cited by 2
Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing
Lau, C. S., Oh, H. M., & Aw, T. C. (2024) · Vaccines · doi:10.3390/vaccines13010009 · Cited by 2
COVID-19 Vaccines - Current State and Perspectives
Abdurakhmonov, I. Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101006 · Cited by 4
García-Mendoza, M., Merino-Sarmiento, N. S., Lucio-Burga, G. D., Fernández-Navarro, M., Pampa-Espinoza, L., Solis, G., Huaringa, M., Palomino, M., Rios, P., & Solari, L. (2022) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2022.393.10875 · Cited by 3
Evaluation of the Abdala Vaccine: Antibody and Cellular Response to the RBD Domain of SARS-CoV-2
Islas-Vázquez, L., Alvarado-Alvarado, Y. C., Cruz‐Aguilar, M., Velázquez-Soto, H., Villalobos-Gonzalez, E., Ornelas-Hall, G., Pérez‐Tapia, S. M., & Martínez, M. D. C. J. (2023) · Vaccines · doi:10.3390/vaccines11121787 · Cited by 2
Grigorova, I. (2021) · System Biology and Physiology Reports · doi:10.52455/sbpr.01.202103011 · Cited by 2
COVID-19 infection after mRNA 1273 vaccine: review of the most frequently asked questions
Vanaparthy, R., Malayala, S. V., Rehman, H., Guttha, S., Mohan, G., Vasireddy, D., & Atluri, P. (2021) · Infezioni in Medicina · doi:10.53854/liim-2903-1 · Cited by 2
Jeong, S., Lee, N., Lee, S. K., Cho, E., Hyun, J., Park, M.-J., Song, W., Jung, E., Woo, H., Seo, Y. B., et al. (2021) · Diagnostics · doi:10.3390/diagnostics12010085 · Cited by 2
Shimamura, Y., Anbo, Y., & Furuta, Y. (2022) · Cureus · doi:10.7759/cureus.23549 · Cited by 2
Inada, M., Ishikane, M., Terada, M., Matsunaga, A., Maeda, K., Iwamoto, N., Ujiie, M., Kutsuna, S., Morioka, S., Ishizaka, Y., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.017 · Cited by 2
Filchtinski, D., Sundberg, M., Berthold, H., Steller, L., Kayser, J., Holz, S., Hinze, M., Braeutigam, O., Schulte-Pelkum, J., & Fiedler, R. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113258 · Cited by 2
Salerno, G., Gentile, G., Luca, O. D., Costanzi, G., Cirelli, G., Giuseppe, B. D. S. D., Marcellini, L., Anibaldi, P., Marcolongo, A., Simmaco, M., et al. (2022) · Viral Immunology · doi:10.1089/vim.2022.0026 · Cited by 2
Ghani, H., Ahmad, L., Sharif, H., Wong, J., Bagol, S. H., Alikhan, M. F., Taib, S., Tan, C. W., Zhu, F., Ong, X. M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-067020 · Cited by 2
Bjarnarson, S. P., & Brynjolfsson, S. F. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac113 · Cited by 2
Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
Masson, L. C., Servian, C. D. P., Jardim, V. H., dos Anjos, D. C. C., Dorta, M. L., Batalha-Carvalho, J. V., Moro, A. M., Romão, P. R. T., Souza, M. B. L. D., Fiaccadori, F. S., et al. (2023) · Vaccines · doi:10.3390/vaccines11071183 · Cited by 2
Identifying Potential Superspreaders of Airborne Infectious Diseases in Construction Projects
Yuan, Z., Ye, Z., Zhang, Y., & Hsu, S. (2023) · Journal of Management in Engineering · doi:10.1061/jmenea.meeng-5497 · Cited by 2
Post-SARS-CoV-2 vaccination specific antibody decrease : Let's get the half-full glass perspective
Béné, M. C., Bittencourt, M. D. C., & Chevallier, P. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.07.027 · Cited by 2
Κοντοπούλου, Κ., Nakas, C. T., & Papazisis, G. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.3989286 · Cited by 2
Antibody titers decline 3-month post-vaccination with BNT612b2Preprint
Favresse, J., Bayart, J., Mullier, F., Elsen, M., Eucher, C., Eechhoudt, S. V., Roy, T., Wieërs, G., Laurent, C., Dogné, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-574216/v1 · Cited by 2
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisPreprint
Anderson, E. J., Jackson, L. A., Rouphael, N., Widge, A. T., Montefiori, D. C., Doria‐Rose, N. A., Suthar, M. S., Cohen, K. W., O’Connell, S. E., Makowski, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1222037/v1 · Cited by 2
Self-citationThuluva, S., Paradkar, V. M., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R. R., Kyasani, M., Manoharan, S., Medigeshi, G. R., Singh, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4055319 · Cited by 2
Nakamura, N., Park, H., Kim, K. S., Sato, Y., Jeong, Y. D., Iwanami, S., Fujita, Y., Zhao, T., Tani, Y., Nishikawa, Y., et al. (2022) · medRxiv · doi:10.1101/2022.07.05.22277283 · Cited by 2
Vaccine-induced immune responses against SARS-CoV-2 infections
Garg, M. K., Maralakunte, M., Kumar, Y., Bhujade, H., Sehgal, I. P., Suri, V., & Garg, S. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00024 · Cited by 1
Anticuerpos Anti SARS-CoV-2, Post-vacunación en Cochabamba, Bolivia
Limachi-Choque, J., & Verduguez-Orellana, A. (2022) · Gaceta Médica Boliviana · doi:10.47993/gmb.v45i1.382 · Cited by 1
Mahmoud, Y., Hathout, A., Amen, R. A., Desouky, S., Shady, R. M., & Fahmy, H. M. (2023) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000386 · Cited by 1
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002718 · Cited by 1
The development of lipid nanoparticle technology for the management of COVID-19
Yingngam, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33002-5.00006-3 · Cited by 1
Gül, N. N., Taheri, S., de Leeuw, S., & Kian, R. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118918 · Cited by 1
Wu, Q., Hu, H., Qin, L., Ma, X., Chen, B., Li, X., Chen, Y., Xing, L., Yang, M., Li, C., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01386-z · Cited by 1
Mesoporous silicon microparticles enhance antiviral immunity and memory responses against SARS-CoV-2
López-Gomez, A., Real-Arévalo, I., Mayol, E., Cendra, J. A., Laxalde-Fernández, D., Nogales‐Altozano, P., Rivas-Pardo, B., Amorós-Pérez, B., Martín-Adrados, B., Juárez, I., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-38583-8 · Cited by 1
COVID-19 Pandemic: Outbreak, Potential Vaccines And Medications
Bhat, R., Soliman, S. S. M., Ahmed, M. M. E., & Husseiny, M. I. (2021) · Russian Open Medical Journal · doi:10.15275/rusomj.2021.0401 · Cited by 1
Is the BCG Vaccine an Answer to Future Pandemic Preparedness?
Khan, N., Rouphael, N., Baden, L. R., & Graciaa, D. S. (2022) · Vaccines · doi:10.3390/vaccines10020201 · Cited by 1
Self-citationThe humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study
Gueguen, M., Khatchatourian, L., Lohéac, C., Dorval, I., Mercier, M., Calloch, R. L., Mahé, K., Rizcallah, M.-J., Hutin, P., Fangous, M. S., et al. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.05.008 · Cited by 1
Kushima, H., Ishii, H., Kinoshita, Y., Koide, Y., Komiya, Y., Kato, J., Umehara, M., Sakata, M., Miyazaki, M., & Ikuta, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185388 · Cited by 1
Andrea Olea, N., Olea, A., Hirmas, M., González, C., Iruretagoyena, M., Munita, J., Pedroni, E., Gómez, M., Cortés, J., & Hormazábal, J. (2022) · International Journal of Health Science · doi:10.22533/at.ed.1592672203118 · Cited by 1
Assessment of Post-Vaccination Immunologic Responses in Inactivated Virus COVID-19 Respondents
Setianingrum, E. L. S., Lidia, K., Ratu, K., & Teron, S. E. (2023) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_477_22 · Cited by 1
Investigating the Current Status of SARS-CoV-2 Antibodies in Hospital Staff
Liu, K.-S., Yang, Y., Hwang, K.-L., & Wu, H. (2023) · Pathogens · doi:10.3390/pathogens12050688 · Cited by 1
Sanchez, J., Martinez, E. S., Loveless, B., Sees, J. P., Zammuto, J., Szurmant, H., Fuchs, S., Crone, P., & Hostoffer, R. (2023) · Journal of Osteopathic Medicine · doi:10.1515/jom-2023-0198 · Cited by 1
Vaccine Nanotechnology for the Prevention of Infectious Diseases
Sontakke, S., Sharma, P. C., Worsham, R., Kadur, K., Bhargavi, C., & Morebise, O. (2023) · Springer eBooks · doi:10.1007/978-3-031-49933-3_4 · Cited by 1
Wang, Q., Wu, Y., Wu, L., Lu, C., Ke, Y., Wang, Y., Gu, L., Shen, Y., & Tan, W. (2023) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/fpd8tj · Cited by 1
Hammadi, A. A. K. A., Alzaabi, A. A., Choker, H. B., Ibrahim, A. A., Ishaq, A., Mahboub, A. E., Dhaheri, R. S. A., Alzaabi, M. N., Collyns, T. A., ElGhazali, G. E., et al. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100698 · Cited by 1
Impfstoffe gegen das SARS-Coronavirus-2
Welte, T. (2021) · Pneumo News · doi:10.1007/s15033-021-2716-x · Cited by 1
An Overview of COVID-19 and Its Vaccines
Rehman, N., & Pandey, A. (2021) · Biology Bulletin Reviews · doi:10.1134/s2079086421070069 · Cited by 1
Does the sixth wave of COVID ‐19 break in Okinawa?
Tomochi, M., & Kono, M. (2022) · Journal of General and Family Medicine · doi:10.1002/jgf2.550 · Cited by 1
Ronicke, S., Osmanodja, B., Budde, K., Jens, A., Hammett, C., Koch, N., Zukunft, B., Bachmann, F., Choi, M., Weber, U., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123291 · Cited by 1
Comparison of COVID-19 Vaccines Introduced in Korea
Lee, C.-G., & Lee, D. (2022) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2022.28.2.67 · Cited by 1
Shen, B., Tan, W., Cai, H., Guo, J., Jiang, L., & Qin, P. (2021) · IEEE International Conference on e-Business Engineering (ICEBE) · doi:10.1109/icebe52470.2021.00034 · Cited by 1
Yau, Y., Mishra, S., Easterling, M., & Kumar, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-9001-3_31 · Cited by 1
Widysanto, A., Prasetya, I. B., Meriyanti, T., Sungono, V., Setiawan, D. L., Gunawan, E., Adiputra, B., Lorens, J. O., Santi, T., Pradhana, C. M. L., et al. (2022) · Infectious Medicine · doi:10.1016/j.imj.2022.10.001 · Cited by 1
Boshku, A. A., Aleksovski, V., Tofoski, G., & Spasova, R. (2022) · PubMed Central · Cited by 1
Belda, F., Mora, O., López‐Martínez, M., Torres, N., Vivanco, A. B., Marfil, S., Pradenas, E., Massanella, M., Blanco, J., Christie, R., et al. (2023) · Plasmatology · doi:10.1177/26348535231202681 · Cited by 1
Zhu, Y., Gu, J., Qiu, Y., & Chen, S. X. (2023) · The Annals of Applied Statistics · doi:10.1214/23-aoas1764 · Cited by 1
Periodic vaccination for post-pandemic management: Insights from and planning beyond COVID-19
Xiao, J., Ayer, T., & Chhatwal, J. (2024) · IISE Transactions on Healthcare Systems Engineering · doi:10.1080/24725579.2024.2340515 · Cited by 1
Hibino, S., Hayashida, K., Ahn, A. C., & Hayashida, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-564670/v1 · Cited by 1
Zojer, N. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00741-1 · Cited by 1
Hoque, A. M., Rahman, M. M., & Das, A. (2021) · medRxiv · doi:10.1101/2021.09.07.21263221 · Cited by 1
Acquisition of resistance to wild-type spike-immune sera by emerging SARS-CoV-2 variantsPreprint
Arase, H., Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-963907/v1 · Cited by 1
The effect of confidence and method of questioning on eyewitness testimony.
Venter, A. R., & Louw, D. A. (2005) · PubMed · Cited by 1
Runnstrom, M. C., & Lee, F. E.-H. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202205-0979le · Cited by 1
Design and Development of mRNA Vaccines to Combat the COVID ‐19 Pandemic
Tombácz, I. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch8 · Cited by 1
Grier, J. T. (2021) · The Conversation · doi:10.64628/aai.4tan6vn6g · Cited by 1
A Retrospective Survey among SARS-CoV-1 Infected Healthcare Workers after Three Years Post-Infection
Huang, S., Urbina, A. N., Chen, Y. A., & Wang, S. (2021) · Pathogens · doi:10.3390/pathogens10091078
Huang, A., Hu, J., & Zhang, H. (2021) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000018
Optimal And Worst Examination Strategies For COVID-19Preprint
Tatsuki, O., Naoki, H., & Igarashi, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-959132/v1
Szawarski, P., & Hillebrandt, D. (2021) · Health Promotion & Physical Activity · doi:10.5604/01.3001.0015.3379
Severe Acute Respiratory Syndrome Coronavirus 2 Serology Testing – A Laboratory Primer
Slev, P. R. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.003
Malipiero, G., & Villalta, D. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.021
Pandemic Analysis V: The Science and Economics of a Vaccine for Ending the Pandemic
Seo, S. N. (2022) · Springer eBooks · doi:10.1007/978-3-030-91021-1_7
Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
Kiewisz, J., Drzyzga, D., Rozanska, K., Krzynowek, E., & Łukaszuk, K. (2022) · Vaccines · doi:10.3390/vaccines10050640
Anderson, E. J., Jackson, L. A., Rouphael, N., Widge, A. T., Montefiori, D. C., Doria‐Rose, N. A., Suthar, M. S., Cohen, K. W., O’Connell, S. E., Makowski, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1594631/v1
Self-citationThuluva, S., Paradkar, V. M., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R. R., Kyasani, M., Manoharan, S., Medigeshi, G. R., Singh, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4053490
Human vaccines & immunotherapeutics: news
(2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1918531
Lestari, R. P., Ajmala, I. E., Fathana, P. B., & Pintaningrum, Y. (2021) · Advances in health sciences research/Advances in Health Sciences Research · doi:10.2991/ahsr.k.220206.069
Takeuchi, M., Esaki, A., Higa, Y., & Nakazono, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263486
Wang, L., Wu, Z., Ying, Z., Li, M., Hu, Y., Shu, Q., Li, J., Ma, Q., Zhang, H., Jiao, W., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4099431
SARS-CoV-2 Antibody Status after the BNT162b2 Vaccine in Healthcare Workers
Onishi, S., YAMAZAKI, A., Kikuchi, K., Shimamura, Y., Sugaya, F., & Anbo, Y. (2022) · Japanese Journal of Infection Prevention and Control · doi:10.4058/jsei.37.10
Mravčík, V., Valachovičová, S. K., & Vobořil, J. (2022) · Central European Journal of Public Health · doi:10.21101/cejph.a7230
COVID-19: A Path to Normalcy at HBCUs
(2022) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2022.04(07).09
Kuzdra, H., Wysokińska‐Miszczuk, J., Wysokiński, K. I., & Wysokiński, M. M. (2022) · Acta Physica Polonica A · doi:10.12693/aphyspola.141.613
The COVID-19 Vaccines: The Current Standpoint
Kim, J., & Thapa, N. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107057
Ocmant, A., Roisin, S., Mathieu, D., Brauner, J., & Leener, F. D. (2022) · Laboratory Medicine · doi:10.1093/labmed/lmac127
Elshamy, A. M., Salem, R., Kamel, N. M., Younes, S., Marie, O., & Hussein, M. (2022) · Advances in Environmental and Life Sciences · doi:10.21608/aels.2022.176421.1023
Uea‐Areewongsa, P., Pinpathomrat, N., Ongarj, J., Sophonmanee, R., Seepathomnarong, P., Seeyankem, B., Surasombatpattana, S., & Intapiboon, P. (2023) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-280722-1420
T Cell Immune Responses against SARS-CoV-2 in the With Corona Era
Oh, J.-E. (2022) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2022.28.4.211
Critical evaluation of censorship during the Covid-19 pandemic
Chongloi, H. (2022) · Mass Communicator International Journal of Communication Studies · doi:10.5958/0973-967x.2022.00021.7
Hughes, R. M., Frey, S., Teles, M. S., Connolly, C. M., Segev, D. L., Werbel, W. A., & Chen, P. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.03.025
The dilemma of choosing the optimum vaccine interval
Menon, T., Balasubramanian, R., Veeraraghavan, G. R., & Perumal, M. N. (2023) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_800_21
Power Hegemony: The New Era of Chinese Socialism with the Character of XI Jinping
Maya, A. J. (2023) · International Journal of Social Service and Research · doi:10.46799/ijssr.v3i5.366
Immunological Characteristics of Unvaccinated Patients with COVID-19 in the Early Pandemic Period
Kim, N., Kim, B., Shin, S., Minn, D., Park, S., Roh, E. Y., Yoon, J. H., & Park, H. (2023) · Laboratory Medicine Online · doi:10.47429/lmo.2023.13.3.212
Metadata
- Authors
- Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., O’Dell, S., Schmidt, S. D., Widge, A. T., Edara, V.-V., Anderson, E. J., Lai, L., Floyd, K., Rouphael, N. G., Zarnitsyna, V., Roberts, P. C., Makhene, M., Buchanan, W., Luke, C. J., Beigel, J. H., Jackson, L. A., Neuzil, K. M., Bennett, H., Leav, B., Albert, J., & Kunwar, P.
- Affiliations
- National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD
- Emory University (US)
- Emmes (United States) (US)
- National Institutes of Health (US)
- NIAID, Bethesda, MD
- Kaiser Permanente Washington Health Research Institute (US)
- University of Maryland, Baltimore (US)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Suthar, Mehul S.
- ORCID
- Doria-Rose, Nicole
- Suthar, Mehul S.
- Makowski, Mat
- O’Connell, Sarah
- McDermott, Adrian B.
- Ledgerwood, Julie E.
- Mascola, John R.
- Graham, Barney S.
- Lin, Bob C.
- Schmidt, Stephen D.
- Widge, Alicia T.
- Edara, Venkata-Viswanadh
- Anderson, Evan J.
- Lai, Lilin
- Floyd, Katharine
- Rouphael, Nadine G.
- Zarnitsyna, Veronika
- Roberts, Paul C.
- Beigel, John H.
- Jackson, Lisa A.
- Neuzil, Kathleen M.
- Bennett, Hamilton
- Leav, Brett
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-10
- Volume
- 384
- Issue
- 23
- Pages
- 2259-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8524784
- OpenAlex
- W3142193311
- Cited by
- 673
- References
- 6
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 40 · 2023: 104 · 2022: 287 · 2021: 199
- FWCI
- 49.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Covid-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine
- North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
- North Carolina Coronavirus Relief Fund
- Coalition for Epidemic Preparedness Innovations
- Georgia Research Alliance
- National Institute of Allergy and Infectious Diseases (AI149644, HHSN272201500002C, P51 OD011132, UM1AI148373, UM1AI148576, UM1AI148684, UM1Al148684-01S1)
- National Center for Advancing Translational Sciences (UL1 TR002243)
- Dolly Parton COVID-19 Research Fund
- Emory Executive Vice President for Health Affairs Synergy Fund award
- Center for Childhood Infections and Vaccines
- Children’s Healthcare of Atlanta
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccination, antibody persistence, humoral immune response, Moderna vaccine, booster vaccination, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adult, Aged, Antibodies, Viral, Half-Life, Humans, Middle Aged, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
